NT-I7 for Kaposi Sarcoma in Patients With or Without HIV

Part of paid clinical trials in San Francisco, California.

Sponsor
Fred Hutchinson Cancer Center
Study ID
NCT04893018
Phase
PHASE1
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This phase I trial studies the best dose and effects of NT-I7 in treating Kaposi sarcoma in patients with or without HIV. NT-I7 works by using a patient's immune system to fight cancer. It is made in a laboratory and is used to boost, direct, or restore the body's natural defenses against cancer. NT-I7 may work better in treating Kaposi sarcoma.

Key Dates

Start date
May 23, 2022
Status verified
Apr 2024
Primary completion
Dec 15, 2023
Completion
Dec 15, 2023

Study Design

Enrollment
8 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment (efineptakin alfa)
    Patients receive efineptakin alfa IM on day 1. Cycles repeat every 9 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity.

Primary Outcome Measure

Percentage of Participants With Adverse Events [ Time Frame: Up to 30 days after last dose of NT-I7, approximately 31 weeks total ]

Locations (3)

FacilityCityStateZIPSite coordinators
Zuckerberg San Francisco General HospitalSan FranciscoCalifornia94110-
National Institutes of Health Clinical CenterBethesdaMaryland20892-
Harborview Medical CenterSeattleWashington98104-

Find similar trials in San Francisco, CA

By condition
HIV
By specialty
Infectious disease
By research site
Zuckerberg San Francisco General Hospital· San Francisco, CANational Institutes of Health Clinical Center· Bethesda, MDHarborview Medical Center· Seattle, WA

Related Studies